Adaptive Biotechnologies News and Activities
Presence
Adaptive Biotechnologies develops immune medicine and diagnostic tools. Its products and services include genomic testing, immune profiling, and research solutions for healthcare providers, biopharma companies, and academic researchers.
Adaptive Biotechnologies products and services overview:
- Genomic testing
- Immune profiling
- Clinical diagnostics
- Research services
- Data analytics
Revenue: ~$170 million
Employees: 700
Headquarters: Seattle, United States (USA)
Adaptive Biotechnologies is one of the...
Adaptive Biotechnologies is a company listed under the stock ticker ADPT (US).
Executives
View the org chart displaying its 30 main executives
Most searched biographies at Adaptive Biotechnologies
- Chad Robins, President, Chief Executive Officer and Director
- Rob Hershberg, Director
- Mike Pellini, Director
Create your alert
to follow the executive moves at Adaptive Biotechnologies.
Biotechnology
Adaptive Biotechnologies has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Adaptive Biotechnologies
- Events - Adaptive Biotechnologies
- Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020 - Adaptive Biotechnologies
- Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference - Adaptive Biotechnologies
- Press Releases - Adaptive Biotechnologies
- Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results - Adaptive Biotechnologies
- Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit - Adaptive Biotechnologies
- Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia - Adaptive Biotechnologies
- Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2 - Adaptive Biotechnologies
- Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease - Adaptive Biotechnologies
- Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock - Adaptive Biotechnologies
- View more press releases Close
Social media about Adaptive Biotechnologies
- Adaptive Biotechnologies on Wikipedia, Google News & Yahoo Finance
- Adaptive Biotechnologies on LinkedIn, X (Twitter) & YouTube
